However, the Bax/Bcl2 ratio was significantly increased at the mRNA level and tended to increase at the protein level (p = 0.146) in the higher dose of KP-13-treated CKD group compared to the sham-operated group (Figs. 8E and F, Figures S8 and S9). The gene discussed is BAX; the disease is chronic kidney disease.